Last reviewed: June 7, 2026

Last updated: June 7, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

The FDA has not halted compounding of semaglutide by licensed 503A pharmacies, though regulatory scrutiny continues around quality standards and marketing claims. PlexusDx partners exclusively with licensed 503A compounding pharmacies to deliver semaglutide injections starting at $149 per month across all 50 states, ensuring patients have uninterrupted access to this proven GLP-1 receptor agonist without insurance requirements.

Current Regulatory Status of Compounded Semaglutide

Licensed 503A compounding pharmacies operate under specific federal guidelines that permit them to create semaglutide when a licensed prescriber writes a valid prescription for an individual patient. The FDA distinguishes between 503A pharmacies (traditional compounders) and 503B facilities (outsourcing sterile manufacturers), with 503A operations maintaining stricter oversight focused on patient-specific formulations. PlexusDx works exclusively with 503A licensed compounding pharmacies to source all semaglutide injections, ensuring compliance with quality standards and state pharmacy board regulations.

Regulatory agencies continue monitoring compounding practices to prevent misrepresentation, contamination risks, and off-label marketing that exceeds clinical evidence. Recent FDA communications have emphasized that compounded semaglutide may be appropriate when brand-name supply is limited or when cost creates barriers to treatment adherence. The compounding industry remains stable for semaglutide formulations, with no current indications that 503A operations will cease manufacturing this medication for legitimate clinical use.

Why Compounded GLP-1 Medications Remain Available

Compounded semaglutide fills a critical access gap for patients facing prohibitive costs, insurance denials, or shortages of brand-name alternatives. While Novo Nordisk's Ozempic and Wegovy expanded production capacity in 2023 and 2024, supply constraints and high list prices persist in certain regions. PlexusDx offers compounded semaglutide injections at $149 per month as a stable, legal alternative that does not require insurance approval, membership fees, or dose-dependent price increases.

Licensed 503A compounding satisfies both clinical demand and regulatory frameworks that recognize patient access as a public health priority. The American Society of Health-System Pharmacists and state pharmacy boards support compounding for conditions where brand-name shortages exist or affordability barriers limit treatment. By maintaining partnerships with established 503A compounders, PlexusDx ensures patients can access proven GLP-1 therapy without disruption from supply volatility or regulatory changes that do not affect legitimate compounding operations.

How PlexusDx Maintains Consistent Supply and Quality

PlexusDx partners with multiple licensed 503A compounding pharmacies across different regions to diversify sourcing and reduce single-point-of-failure risks. Each pharmacy partner maintains state licensure, quality assurance protocols, and compounding certifications that exceed baseline FDA expectations. Semaglutide injection formulations are produced under controlled conditions with pharmaceutical-grade ingredients, sterility testing, and potency verification before shipment to patients.

All PlexusDx medications are accompanied by Certificate of Analysis documentation and patient safety information that reflects current clinical evidence and compounding best practices. The company conducts ongoing audits of pharmacy partners and maintains transparent communication with patients about supply status, medication origin, and any changes to sourcing. If a patient experiences access delays or quality concerns, PlexusDx customer support coordinates alternative solutions without interrupting treatment continuity.

Personalized GLP-1 Therapy: Beyond Supply Certainty

Beyond securing reliable access to compounded semaglutide, PlexusDx offers precision medicine tools that optimize individual treatment outcomes. The Precision Peptide Genetic Test analyzes 14 metabolic pathways and 49 peptide-related genes, including variants in GLP1R (rs6923761), GIPR (rs1800437), FTO (rs9939609), and MC4R (rs17782313) that influence GLP-1 receptor sensitivity and weight loss response. Understanding your genetic predispositions helps prescribers personalize dosing, medication selection, and adjunctive strategies tailored to your biology.

Patients who complete the Precision Peptide Genetic Test gain insights into why certain GLP-1 formulations may work better than alternatives and how lifestyle modifications interact with genetic factors. This data-driven approach reduces trial-and-error treatment cycles and increases confidence in long-term medication selection, whether you choose compounded semaglutide injection, oral semaglutide, tirzepatide, or dual-compound GLP-Squared protocols starting the second month of therapy.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Is compounded semaglutide legal and safe?

Yes. Licensed 503A compounding pharmacies operate under federal law and state pharmacy board oversight, permitted to prepare semaglutide for individual patients with valid prescriptions. PlexusDx sources all semaglutide exclusively from licensed 503A compounders that maintain quality certifications and sterility standards. The FDA does not prohibit 503A compounding of semaglutide when prescribed for legitimate medical purposes.

What happens if compounded semaglutide supply is disrupted?

PlexusDx partners with multiple licensed 503A compounding pharmacies across regions to ensure redundancy and minimize supply interruptions. If a pharmacy partner experiences unexpected issues, the company coordinates alternate sourcing and notifies affected patients immediately. Patients retain the option to switch to alternative GLP-1 formulations (oral semaglutide, tirzepatide, or GLP-Squared) without additional cost at the tier level they selected.

How does PlexusDx pricing stay flat while my dose increases?

PlexusDx charges a flat monthly rate ($149/month for compounded semaglutide injection) regardless of dose escalation. Your dose may need to go up as your body adapts, but your price won't increase across the commitment tiers available. This model removes financial barriers to optimal dosing and ensures affordability as treatment progresses over months or years.

Are compounded medications covered by HSA or FSA accounts?

Yes. PlexusDx compounded GLP-1 medications are HSA/FSA eligible, allowing you to use pre-tax healthcare dollars for treatment costs. This tax advantage reduces your actual out-of-pocket expense and increases financial accessibility for patients with existing healthcare savings accounts. No insurance requirement means no claim denials, prior authorizations, or coverage delays.

How does genetic testing help optimize my compounded semaglutide therapy?

The Precision Peptide Genetic Test ($99 add-on after first month) reveals your genetic predispositions in GLP1R, GIPR, and other metabolic pathways that influence semaglutide response. These 150+ genetic insights help your prescriber determine whether you'll benefit most from semaglutide alone, tirzepatide, or dual-compound approaches, and inform dosing strategies aligned with your biology. Understanding your peptide genetics increases treatment efficacy and reduces the need for medication switches.

Related Reading

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves